engleski

Brain Metastases in Lung Cancer Respond to Erlotinib

Median survival of patients with brain metastases from non-small cell lung cancer (NSCLC) is poor and more effective treatments are urgently needed. The use of targeted agents in these patients is still controversial. There are some case reports and small retrospective case series that suggest successful treating with EGFR TKIs in patients with lung cancer and brain disease. But there are no prospective trials to confirm that. The concomitant of erlotinib and WBRT is probably better than WBRT alone, as been shown by one small retrospective study from 2009. Here we present a case report of efficacy of erlotinib in this setting, although its association with activating mutations in the epidermal growth factor receptor (EGFR) gene has not been assessed yet.

brain metastases; lung cancer

nije evidentirano